Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

GERMANTOWN, Md.--()--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

Management is scheduled to present Wednesday, May 29, 2019 at 10:00am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.

Contacts

Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com

Contacts

Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com